<DOC>
	<DOCNO>NCT02627703</DOCNO>
	<brief_summary>This study multi-center BCCA study evaluate impact Oncotype DX® assay decision make treat physician patient . The Oncotype DX® assay commercially available diagnostic test aid physician 's treatment recommendation breast cancer patient . The study also pharmacoeconomic component .</brief_summary>
	<brief_title>( Oncotype DX® ) Estrogen Receptor Positive ( ER+ ) HER-2 Negative ( HER 2- ) 1-3 Node Positive ( pN1 ) Breast Cancer</brief_title>
	<detailed_description>This study multi-center BCCA study evaluate impact Oncotype DX® assay decision make treat physician patient . The study also pharmacoeconomic component . All eligible patient either physician and/or patient determine result 21 gene recurrence score could provide additional information useful decision make process regard adjuvant chemotherapy ask participate physician participate study . If interested , patient consent study . The physician complete baseline questionnaire document recommend adjuvant systemic therapy ( pre-Oncotype DX® ) . The Oncotype DX® assay order receipt Physician Patient Registration assignment patient study number . The physician discus result Oncotype DX® assay patient result available upon receipt pre-test questionnaire . The physician complete follow-up questionnaire ( document recommend adjuvant systemic therapy post Oncotype DX® ) result Oncotype DX® assay know .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . Operable breast cancer primary tumour ( pT13 ) 2 . Pathological involvement ( microscopic ) 13 lymph node . No minimum number total lymph node need resect . Extranodal extension nodal deposit allow . 3 . Her2Neu negative IHC ( 0 1+ ) FISH current ASCO/CAP guideline 4 . Patient 's tumor must undergo central review GHI must adequate material Oncotype DX® assay . 5 . Patient 's tumor must contain estrogen receptor ( ER+ ) . 6 . Patient must age ( inclusive ) 1879 . 7 . Patient must able give informed consent 8 . Patient adequate performance status ( PS ECOG 0,1 Karnofsky ≥70 ) medically fit candidate treatment cancer systemic chemotherapy addition hormonal therapy contraindication either systemic therapy maneuver 1 . Patients ER negative tumor ( ER ) local central BCCA assessment 2 . Patients HER2 positive tumor local central BCCA assessment 3 . Patients four lymph node positive disease . 4 . Lymph node involvement isolate tumor cell cell IHC ( less 200 cell and/or ≤0.2 mm ) 5 . Patients know metastatic breast cancer . 6 . Patients unable give consent understand write language . 7 . Patients poor performance status ( ECOG 24 ) consideration adjuvant chemotherapy adjuvant hormonal therapy would contraindicate . 8 . Pregnant woman consideration adjuvant chemotherapy adjuvant hormonal therapy would contraindicate . 9 . Patients tumor GHI central pathological review appear inadequate Oncotype DX® assay .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>